BCN057, is a novel small molecule drug being licensed from the University of California Los Angles (UCLA) that has been found to protect normal tissue against radiation damage. This molecule is being developed under a cooperative agreement with the Biomedical Advanced Research and Development Authority (BARDA). This molecule is currently in the preclinical in life phase.
BCN Bioscience has a focus on the development of novel monoclonal antibodies (mABs) against endothelial-derived drug targets. BCN has explored multiple mABs against gene targets that affect breast and colon cancer, and is currently performing definitive preclinical studies with BCN303 as its lead candidate. Investigative efforts are underway regarding the diagnostic potential of this target. BCN303 is currently in the preclinical phase with DMPK and toxicology studies underway.
BCN is currently engaged in the licensing of other assets, including those intended to address lung cancer indications such as BCN112. This program is being supported by the National Cancer Institute (NCI) for indications in metastatic lung cancer.